Biosceptre: A New Approach to Cancer Research

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Biosceptre: A New Approach to Cancer Research
Released on: November 27, 2009. © PharmaVentures Ltd
Share/save this page:
Follow us:
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks with Alan Bootes, Chairman of Biosceptre International Ltd.

Filmed at AusBiotech 2009, they discuss:

• Biosceptre's unconventional approach to cancer
• the patents involved in Biosceptre's work
• partnering with other firms
• Alan's future hopes for Biosceptre's Biomarker
Biosceptre's unconventional approach to cancer.
Fintan Walton:
Hello and welcome to Pharmatelevision news review here in Melbourne Australia. On this show I have Alan Bootes who is chairman of Biosceptre International Ltd based in Sydney Australia, welcome to the show.
Alan Bootes:
Thank you very much Fintan Walton.
Fintan Walton:
Biosceptre is a biotech company it's a privately held company, what sets Biosceptre apart from other companies in the biotech sector?
Alan Bootes:
We are in the immunological field looking at oncology solutions through immunological approaches that put us in with several hundred perhaps a thousand other small biotech's around the world. What sets Biosceptre apart is the is the approach we are taking, conventional wisdom and the path that most companies are following is based on the philosophy that every cancer is different and people are studying in great and greater detail the individual characteristics of like of each cancer type to understand how they differ from each other, then looking for a target and enter that target building antibodies and looking for diagnostics or treatment modalities that's the conventional approach. Biosceptre scientists stumbled upon something which has a potential to stand up whole concept of personalized medicine, targeted medicine on a tip. They have discovered a single cancer marker which is being this observed on every single type of cancer observed so far and that's some I think different sort of cancer so there are many others out there but the point is we have never looked yet at cancer tissue which has not exhibited this particular marker and the company has been engaged for the last eight to nine years in developing a range of antibodies which uniquely bind to that marker and not to any other types of marker or any other type of cells.
The Patents involved in Biosceptre's work
Fintan Walton:
So what is this biomarker?
Alan Bootes:
It's a non functional form of a receptor which is been world recognized called P2X7. P2X7 has a primary role in normal cell apoptosis in other words when the cell is due to die P2X7 is expressed on its surface it opens a port and also flood of calcium into the cell, stimulates for the caspase pathway and many other factors and the cell dies. In this case of cancer cells this P2X7 is present always not just at the time of theoretical cell death and it's in a non functional format, this has a different physical characteristic in all P2X7 and as I say its ubiquitous to almost all cancer cells and this non functional form it seems unable to bind to ATP and sort of form its proper role in a cell death.
Fintan Walton:
Okay so it's in a form latent formal in effect?
Alan Bootes:
Effectively yes.
Fintan Walton:
Yeah. So what is the patent status for this particular bio marker both from a diagnostic point of view but also from a therapeutic point of view?
Alan Bootes:
Biosceptre has patents on the on the non functional form of P2X7 in cancer diagnosis and therapy. Very broad ranging patents and they have been filed in all the major jurisdictions and granted in most and also we have a whole sweet of patents on the antibodies which have been developed to bind two non functional P2X7, it's a very very strong patent family.
Partnering with other firms
Fintan Walton:
SoBiosceptre and it you are involved in developing this obviously as said both of diagnostic and therapeutic, how can a company of your size do that effectively?
Alan Bootes:
We are very small and obviously we can't do it alone. We know that this receptor has a great potential as a immunity to chemical diagnostic agent that's relatively simple application but we have also found that the antibodies which bind should are able to kill to bind to most types of cancer cell and to kill a great number in in-vitro tests. So there is potential for therapeutic applications as well as diagnostic applications. We can't do that alone, will be looking to a partner with companies who have the financial resources and particularly knowledge to advance the technology and bring to market in due course.
Fintan Walton:
And the diagnostic antibody is currently available for licensing?
Alan Bootes:
The diagnostic is available for licensing and application in skin cancer is also available for licensing and quite frankly we are open to look for financial and technical partners on the systemic side because that's the biggest challenges and also of course the biggest opportunity.
Alan Bootes's future hopes for Biosceptre's Biomarker
Fintan Walton:
Right. And in the end what's your hope and vision for this bio marker?
Alan Bootes:
Well everybody says that this discovery is too good to be true and at first blushed at is because it only does stand a lot of conventional think on a tip but if it is true it is profoundly important. So our vision for the future is that one day in the not too distant future this these antibodies and this marker will be widely used and become a very valuable identity to cancer therapy and save a lot of patients life.
Fintan Walton:
Alan Bootes thank you very much indeed for coming on the show.
Alan Bootes:
Thank you Fintan Walton.
Alan Bootes
Alan Bootes, Chairman of the Board Mr Alan Bootes recently retired after a 37 year career as a global manager with Pfizer Inc, the world's leading Pharmaceutical and Animal Health Products Company. Having built a reputation as an organization development and turnaround specialist through roles in Asia and Africa / Middle East, he subsequently led Pfizer country businesses in Taiwan, Canada (where he lifted annual sales from $50 million, #30 rank, to over $500 million and industry leader in 9 years) and lastly Japan, where in 5 years he took Pfizer from #10 to #1 rank in sales. Alan Bootes also served as Chairman of the pharmaceutical industry associations inTaiwan, Canadaand Japan, where he played a leading role in health policy development together with government officials and other stakeholders. He brings to the board valuable experience in leadership, organization development and international marketing, especially in the Asian region. He has completed his BEc (Ag) (Univ. New Eng).
Biosceptre International is a public, unlisted biotechnology company based in Sydney, Australia that is developing and commercializing antibodies to address a wide range of applications in the diagnosis and treatment of cancer. Biosceptre's Vision is to make a significant contribution to the diagnosis and treatment of cancer worldwide and provide a significant return to their shareholders. This will be achieved through advancing development of various applications of their proprietary cancer marker / target to the point where they can be acquired and commercialized by major global pharmaceutical companies. P2X7 is a major cellular receptor responsible for normal programmed cell death. Biosceptre's technology is based on the fundamental discovery of a subtly changed non-functional form of P2X7 nf-P2X7 that is found on cells of all solid tumors, but not on cells of normal tissues. Biosceptre has patents aroundP2X7 and nf-P2X7 as a diagnostic marker and therapeutic target in human and animal cancers. The Company has developed and continues to develop an inventory of antibodies and antibody constructs which specifically target the non-functional forms of the P2X7receptors which are found on the majority of all cancer types and have application in both therapeutic and diagnostic areas.